MRKR: Marker Therapeutics, Inc. Common Stock Company Profile & Statistics

About

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of innovative peptide and nucleic acid-based immunotherapeutic vaccines for the treatment and eradication of cancer, including metastatic cancer. The company's product pipeline consists of MultiTAA T Cell Therapy, TPIV200 and TPIV100/110 which are in clinical stage. Marker Therapeutics Inc., formerly known as TapImmune Inc., is based in FL, United States.

Info & Links

CEO

Juan Vera

Headquarters

2450 Holcombe Blvd, Suite BCM-A
Houston, TX 77021, UNITED STATES

Auditor

Marcum LLP

Share holders

Employees

Marker Therapeutics, Inc. Common Stock Statistics

Valuation Measures

Market Capitalization²

12.98M

Enterprise Value

-303.78K

Enterprise Value/EBITDA(ttm)

0.02

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

3.40

Price to Book(mrq)

1.34

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

100.00%

Operating Margin(ttm)

-224.46%

Profit Margin(ttm)

-437.85%

Return on Equity(ttm)

-101.87%

Return on Invested Capital(ttm)

-104.94%

Return on Assets(ttm)

-83.02%

Income Statement

Revenue(ttm)

5.70M

Revenue Per Share(ttm)

0.50

Gross Profit(ttm)

5.70M

EBITDA(ttm)³

-13.18M

Net Income Available to Common(ttm)

-12.78M

Diluted EPS(ttm)

-1.33

Share Statistics

Beta (5Y Monthly)

1.43

52-Week Change

-72.60%

S&P 500 52-Week Change

16.67%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

11.31M

Dividend Yield

0.00%

Float⁴

9.67M

% Held by Insiders

14.50%

% Held by Institutions

22.39%

Balance Sheet

Total Cash(mrq)

13.69M

Total Cash Per Share(mrq)

1.21

Total Debt(mrq)

411.30K

Total Debt/Equity(mrq)

2.84%

Current Ratio(mrq)

6.79%

Quick Ratio(mrq)

6.79%

Book Value Per Share(mrq)

1.29

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.50

Free Cash Flow(ytd)

-5.50M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

MRKR

Marker Therapeutics, Inc. Common Stock

Marker Therapeutics, Inc. Common Stock Profile